Abstract
Amyloid beta (Aβ) binding alcohol dehydrogenase (ABAD) is a cellular cofactor for promoting (Aβ)-mediated mitochondrial and neuronal dysfunction, and cognitive decline in transgenic Alzheimer’s disease (AD) mouse models. Targeting mitochondrial ABAD may represent a novel therapeutic strategy against AD. Here, we report the biological activity of small molecule ABAD inhibitors. Using in vitro surface plasmon resonance (SPR) studies, we synthesized compounds with strong binding affinities for ABAD. Further, these ABAD inhibitors (ABAD-4a and 4b) reduced ABAD enzyme activity and administration of phosphonate derivatives of ABAD inhibitors antagonized calcium-mediated mitochondrial swelling. Importantly, these compounds also abolished Aβ-induced mitochondrial dysfunction as shown by increased cytochrome c oxidase activity and adenosine-5'-triphosphate levels, suggesting protective mitochondrial function effects of these synthesized compounds. Thus, these compounds are potential candidates for further pharmacologic development to target ABAD to improve mitochondrial function.
Keywords: ABAD inhibitors, adenosine-5'-triphosphate, amyloid beta, benzothiazole amino phosphonates, cytochrome c oxidase, mitochondrial dysfunction.
Current Alzheimer Research
Title:Identification of Human ABAD Inhibitors for Rescuing Aβ-Mediated Mitochondrial Dysfunction
Volume: 11 Issue: 2
Author(s): Koteswara R. Valaasani, Qinru Sun, Gang Hu, Jianping Li, Fang Du, Yaopeng Guo, Emily A. Carlson, Xueqi Gan and Shirley S. Yan
Affiliation:
Keywords: ABAD inhibitors, adenosine-5'-triphosphate, amyloid beta, benzothiazole amino phosphonates, cytochrome c oxidase, mitochondrial dysfunction.
Abstract: Amyloid beta (Aβ) binding alcohol dehydrogenase (ABAD) is a cellular cofactor for promoting (Aβ)-mediated mitochondrial and neuronal dysfunction, and cognitive decline in transgenic Alzheimer’s disease (AD) mouse models. Targeting mitochondrial ABAD may represent a novel therapeutic strategy against AD. Here, we report the biological activity of small molecule ABAD inhibitors. Using in vitro surface plasmon resonance (SPR) studies, we synthesized compounds with strong binding affinities for ABAD. Further, these ABAD inhibitors (ABAD-4a and 4b) reduced ABAD enzyme activity and administration of phosphonate derivatives of ABAD inhibitors antagonized calcium-mediated mitochondrial swelling. Importantly, these compounds also abolished Aβ-induced mitochondrial dysfunction as shown by increased cytochrome c oxidase activity and adenosine-5'-triphosphate levels, suggesting protective mitochondrial function effects of these synthesized compounds. Thus, these compounds are potential candidates for further pharmacologic development to target ABAD to improve mitochondrial function.
Export Options
About this article
Cite this article as:
Valaasani R. Koteswara, Sun Qinru, Hu Gang, Li Jianping, Du Fang, Guo Yaopeng, Carlson A. Emily, Gan Xueqi and Yan S. Shirley, Identification of Human ABAD Inhibitors for Rescuing Aβ-Mediated Mitochondrial Dysfunction, Current Alzheimer Research 2014; 11 (2) . https://dx.doi.org/10.2174/1567205011666140130150108
DOI https://dx.doi.org/10.2174/1567205011666140130150108 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology Excitotoxicity as a Target Against Neurodegenerative Processes
Current Pharmaceutical Design Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Factors of Rapid Cognitive Decline in Late Onset Alzheimer's Disease
Current Aging Science Antiatherosclerotic and Cardioprotective Effects of Time-Released Garlic Powder Pills
Current Pharmaceutical Design α-Melanocyte Stimulating Hormone as a Potential Therapy for Alzheimer's Disease
Current Alzheimer Research Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
Current Neuropharmacology RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Drugs for AIDS
Mini-Reviews in Medicinal Chemistry Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System
Current Neuropharmacology Nanoparticle-Based Gene Therapy Intervention for Stroke Treatment: A Systematic Review
Current Gene Therapy Non-Analgesic Effects of Opioids: Opioid-induced Nausea and Vomiting: Mechanisms and Strategies for their Limitation
Current Pharmaceutical Design Social Network Analysis of Dementia Wards in Psychiatric Hospitals to Explore the Advancement of Personhood in Patients with Alzheimer’s Disease
Current Alzheimer Research Nocturnal Hypertension, Nondipping Phenomenon and Target Organ Damage in Obstructive Sleep Apnea Patients - The Bad and the Worse
Current Respiratory Medicine Reviews A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials
Current Alzheimer Research Neuroprotective Mechanisms as Treatment Strategy in Alzheimers disease
Current Medicinal Chemistry - Central Nervous System Agents Dopaminergic Enhancement of Cognitive Function
Current Pharmaceutical Design Obesity-Induced Cerebral Hypoperfusion Derived from Endothelial Dysfunction: One of the Risk Factors for Alzheimer's Disease
Current Alzheimer Research Islet Amyloid Polypeptide (IAPP): A Second Amyloid in Alzheimer's Disease
Current Alzheimer Research Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease
Current Pharmaceutical Design